LDS/Medical Tests/Lysoganglioside GM1 Antibody, IgG

Lysoganglioside GM1 Antibody, IgG

The Lysoganglioside GM1 receptor (Lyso GM1) Antibody, IgG assay measures the antibody titer against the neuronal antigen Lysoganglioside GM1 and compares this measurement to a normal control titer against Lysoganglioside GM1. Study of patients with Sydenham chorea revealed IgG antibodies directed against the group A streptococcal carbohydrate epitope GlcNAc and also against lysoganglioside and GM1 ganglioside but not to other gangliosides. The anti-neuronal autoantibodies found in the serum and cerebrospinal fluid of Sydenham chorea patients also signaled SK-N-SH human neuronal cells in culture to activate the calcium calmodulin protein kinase II (CaMKII) inside the human neuronal cells when treated with the human monoclonal antibodies (mAbs), serum antibodies (IgG) or cerebrospinal fluid antibodies (IgG). It was also shown that lysoganglioside blocked the binding of the serum or cerebrospinal fluid IgG to the caudate putamen region of human brain. During convalescence, these autoimmune antibodies receded to normal levels. The results revealed that improvement of patient symptoms was associated with reduction in anti-lysoganglioside antibody and the reduction of CaMKII antibody-mediated signaling of human neuronal cells.

These remarkable findings from Sydenham chorea patients was published for the first time in *Nature Medicine* in 2003. In 2006, a similar study of a PANDAS patient sera was published in the *Journal of Neuroimmunology*. This showed that the antibodies (IgG) in PANDAS patient sera also reacted with lysoganglioside and signaled molecules at the surface of human neuronal cells to activate the CaMKII enzyme in the human neuronal cells. These studies showed that lysoganglioside could inhibit the reaction of the serum or cerebrospinal fluid antibodies (IgG) reactivity with human caudate putamen brain tissue from human basal ganglia. CSF from PANDAS patients also contained these same IgG antibodies, which signaled human neuronal cells to activate the CaMKII. These results in humans suggest an antibody-mediated mechanism in disease.

The Lysoganglioside GM1 (LYSO-GM1) Antibody, IgG is one of the five tests which comprise The Cunningham Panel™ of Tests. The Cunningham Panel™ tests measure human serum Immunoglobulin G (IgG) levels by Enzyme-Linked ImmunoSorbent Assay (ELISA) directed against: Dopamine D1 Receptor (DRD1), Dopamine D2L Receptor (DRD2L), Lysoganglioside-GM1 (LYSO-GM1) and Tubulin (TUB). ELISA results are determined by measuring the colorimetric intensity at a specific wavelength which is directly proportional to the amount of antibody in the sample. The fifth assay of this panel measures the specific activity of calcium/calmodulin-dependent protein kinase II (CaM KII) induced by the patient’s serum in cultured human neuronal cell lines compared to controls. This panel measures the level of these antibodies, and the ability of the patient’s sera to stimulate CaM KII at a single point in time. The Cunningham Panel™ of Tests is a proprietary test panel exclusively offered by Moleculera Labs. For more information please see .

- As an aid in diagnosis and management Pediatric Autoimmune Neuropsychiatric Disorder Associated with Strep (PANDAS) - As an aid in diagnosis and management of pediatric acute-onset neuropsychiatric syndrome (PANS) - As an aid in diagnosis and management of Sydenham's chorea (post Rheumatic Fever) - As an aid in diagnosis and management of Autism spectrum disorder, specifically regressive autism, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of treatment resistant psychiatric illnesses and symptoms that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of chronic depression that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of anxiety disorders that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of ADHD/ADD that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of, OCD that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of Tourette’s Syndrome, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of bipolar depression, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of new onset enuresis/incontinence, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of rage disorder, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of ODD, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of behavioral regression, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of cognitive decline, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of sensory abnormalities, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of dysgraphia, that could have an anti-neuronal autoimmune basis - As an aid in diagnosis and management of anorexia, that could have an anti-neuronal autoimmune basis
If any one (1) or more of these five (5) assay values is elevated, it may indicate a clinically significant autoimmune neurological condition. *Note: It is important to note that the degree of elevation in assay values may not necessarily correlate with degree of symptom severity. Any value above normal ranges may correlate with symptomatology. Results may vary depending on the patient’s condition and status, whether they are on immunosuppressive agents, corticosteroids or other immune modulatory therapy, and the length of time post treatment.*
  Anti-Dopamine Receptor D1 (titer) Anti-Dopamine Receptor D2L (titer) Anti-Lysoganglioside GM1 (titer) Anti-Tubulin (titer) CaM Kinase II (% of baseline)
Normal Ranges 500 - 2,000 2,000 - 8,000 80 - 320 250 - 1,000 53 - 130
Normal Mean 1,056 6,000 147 609 95
Enzyme-Linked Immunosorbent Assays (ELISAs)

Serum (Red top tube).

4-5 mL serum collected in red-top glass tube with no additives or gel barrier. Ship on two fully frozen 8-ounce ice packs, overnight only Monday-Thursday. Do not ship on Friday or before a US holiday.

Stability

  • Frozen: 1 year
IgG and IgM titer measurement for any known or suspected past, recent or current infection, testing for general metabolic and genetic markers such as GAD 65, MTHFR; testing for IgG and/or IgM to EBV, CMV, HHV6 and other viruses in the Herpes family, Lyme Disease IgG, IgM; Babesisia and Bartonella antibodies, ASO titer, DNaseB titers, Group A strep blood cultures.
Approximately 2-3 weeks
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  •  J Child Adolesc Psychopharmacol. 2015;25(1):76-85. [PMID: 25658702]
  •  J Child Adolesc Psychopharmacol. 2015;25(1):3-13. [PMID: 25325534]
  •  Nature Medicine. 2003;9(7):914-920. [PMID: 12819778]
  •  PLoS One. 2013;8(9):e73516. [PMID: 24073196]
  •  Acta Physiol (Oxf). 2016;216(1):90-100. [PMID: 26454143]
  •  Immunology. 2007;178:7412-7421. [PMID: 17513792]